Consecutive daily low-dose S-1 adjuvant chemotherapy after radical treatment for squamous cell carcinoma in head and neck cancer
Consecutive daily low-dose S-1 adjuvant chemotherapy after radical treatment for squamous cell carcinoma in head and neck cancer
复制标题
DOI：
10.3109/00016489.2011.590153
复制
发表时间：
2011-10-01
影响因子：
1.4
通讯作者：
Ikeda, Minoru
中科院分区：
文献类型：
--
作者：
Furusaka, Tohru;Tanaka, Akane;Ikeda, Minoru
结论。连续每日小剂量S-1治疗毒性小，疗效不逊于常规给药方案。对于由于不良反应而难以继续使用S-1常规给药方案的患者，连续每日低剂量的S-1化疗似乎是一种治疗选择。目的：评价小剂量S-1在辅助环境下连续每日治疗的安全性和有效性。方法：对52例晚期头颈部鳞状细胞癌根治术后无局部残留、无淋巴结转移或无远处转移的患者进行研究。在得到患者的知情同意后，S-1通常剂量的一半每天服用，持续2年。评估了该方法的安全性、可行性和有效性。结果：52例患者中51例出现血液学毒性(98.1%)，而3级血液学毒性仅2例(3.8%)。非血液学毒性15例(28.8%)，均为1级。43例(82.7%)可在不减少剂量的情况下完成2年的化疗。3年无瘤生存率和3年生存率分别为82.6%和94.0%。
Conclusion. Consecutive daily low-dose S-1 therapy was less toxic and its efficacy was not inferior to the conventional administration schedule. Consecutive daily low-dose S-1 chemotherapy appears to be a treatment option for patients in whom it is difficult to continue the conventional administration schedule of S-1 due to adverse events. Objective: To evaluate the safety and efficacy of consecutive daily low-dose S-1 therapy in an adjuvant setting. Methods: This study investigated 52 patients with absence of local residual tumor, lymph node metastasis or distant metastasis after radical treatment for advanced head and neck squamous cell carcinoma. After receiving informed consent from patients, half of the usual dose of S-1 was administered daily for 2 years. The safety, feasibility, and efficacy of this approach were evaluated. Results: Hematologic toxicity was seen in 51 of 52 patients (98.1%), but grade 3 hematologic toxicity was found in only 2 patients (3.8%). Nonhematologic toxicity was observed in 15 patients (28.8%) and all were grade 1. Forty-three patients (82.7%) were able to complete the chemotherapy for 2 years without dose reduction. The 3-year disease-free survival rate and 3-year survival rate were 82.6% and 94.0%, respectively.